Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06620744 · ClinicalTrials.gov registry record · NA

Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin

A NA study, sponsored by SB Technology.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT06620744 is a NA study that has completed, run by SB Technology. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06620744, a NA study, has completed, sponsored by SB Technology.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This prospective device study will examine the feasibility of MCG data collection in a hospital setting using the SandboxAQ MCG device as a potential method to more accurately and quickly quantify cardiac disease of patients with elevated Troponin.

Interventions

  • DEVICE Sponsor MCG deivce

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-09-21
Est. Completion 2025-04-15
Phase NA

Sponsor

SB Technology

3 total trials

What the Registry Record Tells You About NCT06620744

The ClinicalTrials.gov registry entry for NCT06620744 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SB Technology, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Sponsor MCG deivce is the first listed.

NCT06620744 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06620744 about?

NCT06620744 is a clinical study titled "Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin". This prospective device study will examine the feasibility of MCG data collection in a hospital setting using the SandboxAQ MCG device as a potential method to more accurately and quickly quantify cardiac disease of patients with elevated Troponin.

What is the current status of trial NCT06620744?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2024-09-21. Estimated completion is 2025-04-15.

What interventions are being tested in trial NCT06620744?

The interventions under investigation include: Sponsor MCG deivce (DEVICE).

Who is sponsoring clinical trial NCT06620744?

This trial is sponsored by SB Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.